BBB-permeable Hsp90 inhibitors, 17-AAG and PU-DZ8, were used to decrease the levels of phosphorylated tau in the AD model (Luo et al., 2007) and to inhibit neurodegeneration in a fly HD model (Fujikake et al., 2008). This evidence concerns the gene HSP90AB1 and Alzheimer disease.